Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-73763989
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
JNJ-73763989 (also known as JNJ-3989) is a liver-targeted small interfering RNA (siRNA) therapeutic developed by Janssen Research and Development in collaboration with Arrowhead Pharmaceuticals for the treatment of chronic hepatitis B virus (HBV) infection. The drug utilizes RNA interference (RNAi) to target and degrade HBV viral RNAs, specifically through two N-acetylgalactosamine (GalNAc)-conjugated siRNA triggers: JNJ-73763976 (S-trigger) and JNJ-73763924 (X-trigger). These triggers target the hepatitis B surface antigen (HBsAg) and the hepatitis B x protein (HBx) open reading frames, respectively. By degrading pregenomic RNA and all viral transcripts, JNJ-73763989 aims to reduce levels of all HBV viral proteins, potentially enabling the restoration of the host immune response. It is administered via subcutaneous injection and has been evaluated in Phase 2 clinical trials, including the REEF-1 and REEF-2 studies, frequently in combination with capsid assembly modulators and nucleos(t)ide analogues.
- Other names
- JNJ-3989JNJ3989JNJ 3989
02
Targets
Hepatitis B virus surface antigen mRNA / S open reading frame-containing transcripts
Beyond the preview
Go deeper on JNJ-73763989.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-73763989.